摘要
比较拉米夫定联合干扰素和单用治疗慢性乙型肝炎对血清HBV清除动力学的影响,探讨联合治疗的安全性和抗病毒效果。88例HBeAg和HBVDNA均阳性慢性乙肝患者随机分为三组:联合组30例,给予拉米夫定100mg口服,每日1次,干扰素a3MU,肌肉注射,每周3次。拉米夫定组22例,干扰素组36例。疗程均为6个月。治疗结束时,ALT复常率联合组(100％)和拉米夫定组(95.4％)均明显高于干扰素组(44.4％)(P<0.05)。治疗1个月时,血清HBVDNA下降幅度联合组和拉米夫定组均显著高于干扰素组(P<0.05)。治疗结束时,血清HBVDNA阴转率联合组(100％)和拉米夫定组(100％)均明显高于干扰素组(44.4％)(P<0.05);血清HBeAg阴转率联合组(63.3％)明显高于拉米夫定组(31_8％)和干扰素组(38.9％)(P<O.05)。血清HBeAg转换率联合组(56.7％)明显高于拉米夫定组(13.64)和干扰素组(27.78％)(P<0.05)。拉米夫定和干扰素联合治疗慢性乙型肝炎是安全的,抗病毒效果优于单一药物治疗。
To study the efficacy and safety of Lamivudine combined with Interferon alpha (IFN - α) on treatment of chronic hapeti-tis B with HBVDNA and HBeAg positive. 88 patients were randomly divided into combined curative group (Lamivudine and IFN -α)(n= 30) , Lamivudine group (n= 22) and IFN- α group (n= 36) . The patients in combined curative group received lamivudine 100mg daily and IFNa 3MU three times weekly for six months. The patients in Lamivudine group recieved lamivudine 100mg daily for six months. The patients in IFN - α group received IFN - α 3MU for sk months. To observe the improvement rate of clinical symptoms, the answer rate of liver function, the answer rate of virus and the side effects. At the end of treatment, clinical symptoms improved markely in three groups, the rate of ALT normalization in combined curative group and in Lamivudine group were higher than that in IFN - α group (100% , 95.4%vs 44.4% , P<0.05). After sk months, HBVDNA negative rate in combination group and lamivudine group was significantly higher than that in IFN - α group, respectively (100%, 95.4% vs 44.4% , P < 0.05) . Proportions of HBeAg negative in combination group were higher than in lamivudine group and in IFN - α group, respectively (63.3%vs 31.8%, 38.9%, P < 0.05). HBeAg seroconversion rate in combination group was higher than in lamivudine group and in IFN - α group, respectively (56.7% vs 13.64%, 27.7%, P < 0.05). The results suggest that combination therapy of lamivudine and IFN - α should be safe and efficient, and superior to lamivudine or IFN - α alone.
出处
《临床肝胆病杂志》
CAS
北大核心
2003年第1期33-35,共3页
Journal of Clinical Hepatology
